



Targeted Treatments in Cancer

Guest Editor:

Prof. Dr. Kazuko Kaneda-Nakashima

Institute for Radiation Sciences,
Osaka University, 2-4 Suita,
Osaka 565-0871, Japan

Deadline for manuscript
submissions:

closed (18 August 2023)

Message from the Guest Editor

In recent years, the survival rate of cancer patients has increased, due to the development of various treatments. However, some cancers, such as pancreatic cancer, are extremely resistant to treatment. One approach uses antibodies or chemicals conjugated to radionuclides, which provide specific radiotherapy. Nuclear medicine treatment is less invasive than surgery, and is suitable for difficult-to-treat cancer cases.

We focus on researching the usefulness of nuclear medicine treatments, and we aim to drive the development of novel therapeutic agents. Since molecular biology and basic scientific studies are indispensable for the development of technology in nuclear medicine, we will prioritize basic research over clinical trials/data.

Keywords:

- TAT (targeting alpha therapy)
- nuclear medicine
- cancer treatment
- imaging
- radioisotope (RI)
- surface marker
- TRT (targeted radioisotope therapy)





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Maurizio Battino

Department of
Odontostomatologic and
Specialized Clinical Sciences,
Sez-Biochimica, Faculty of
Medicine, Università Politecnica
delle Marche, Via Ranieri 65,
60100 Ancona, Italy

Message from the Editor-in-Chief

The International Journal of Molecular Sciences (*IJMS*, ISSN 1422-0067) is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, molecular biophysics, molecular medicine, and all aspects of molecular research in chemistry. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Inorganic Chemistry)

Contact Us

*International Journal of Molecular
Sciences* Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/ijms
ijms@mdpi.com
X@IJMS_MDPI